Generic Name:
bevacizumab and lomustine
Project Status:
Active
Therapeutic Area:
Recurrent glioblastoma multiform
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0318-000
Call for patient/clinician input closed:
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy.
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.